Clomethiazole acute stroke study in ischemic stroke (CLASS-I): Final results

Stroke

Volumn 33, Issue 1, 2002, Pages 122-128

  Lyden, P ^a,j   Shuaib, A ^b   Ng, K ^c   Levin, K ^d   Atkinson, R P ^e   Rajput, A ^f   Wechsler, L ^g   Ashwood, T ^h   Claesson, L ^h   Odergren, T ^h   Salazar Grueso, E ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Ocala Medical Center   (United States)

^d Neurology Group of Bergen County   (United States)

^e Mercy General Hospital   (United States)

^f ROYAL UNIVERSITY HOSPITAL   (Canada)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ ASTRAZENECA   (United Kingdom)

^j OPC   (United States)

more..

Author keywords

Antithrombotic therapy; Clomethiazole; GABA; Neuroprotection; Stroke

Indexed keywords

CLOMETHIAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STROKE; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL FIELD DEFECT;

ACUTE DISEASE; ADULT; AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHLORMETHIAZOLE; DOUBLE-BLIND METHOD; FEMALE; GABA MODULATORS; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; TIME FACTORS;

EID: 18244392468     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs0102.101478     Document Type: Article

References (38)

1. Epidemiology of stroke
2. Treatment of acute ischemic stroke
3. The Greater Cincinnati/Northern Kentucky Stroke Study preliminary first-ever and total incidence rates of stroke among blacks
4. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke
5. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis: Not a panacea for ischemic stroke
6. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
7. GABA and neuroprotection
8. GABA potentiation: A logical pharmacological approach for the treatment of acute ischaemic stroke
9. Neuroprotective activity of chlomethiazole following transient forebrain ischaemia in the gerbil
10. Clomethiazole treatment ameliorates the motor disability incurred by focal cerebral ischaemia in a non-human primate
11. Clomethiazole protects against hemineglect in a primate model of stroke
12. The neuroprotective effect of chlomethiazole on ischaemic neuronal damage following permanent middle cerebral artery ischaemia in the rat
13. The effect of chlomethiazole on neuronal damage in a model of transient focal ischaemia
14. Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations
15. Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
16. Functional evaluation: The barthel index
17. The Clomethiazole Acute Stroke Study (CLASS): Efficacy results in a subgroup of 545 patients with total anterior circulation syndrome
18. The Clomethiazole Acute Stroke Study (CLASS): Safety results in 1356 patients with hemispheric stroke
19. The Clomethiazole Acute Stroke Study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a Phase III Trial in the United States and Canada
20. The Barthel ADL Index: A standard measure of physicaI disability?
21. Stroke rehabilitation: Analysis of repeated Barthel Index measures
22. Cerebral vascular accidents in patients over the age of 60: Prognosis
23. Interobserver agreement for the assessment of handicap in stroke patients
24. Improved reliability of the NIH stroke scale using video training
25. Multicentre trial of hemodilution in acute ischemic stroke: Background and study protocol
26. Reliability of Scandinavian neurological stroke scale
27. Stroke scores and scales
28. Classification and natural history of clinically identifiable subtypes of cerebral infarction
29. Classification of subtype of acute ischemic stroke: Definitions for use in a multicentre clinical trial
30. Reliability of the activities of daily living scale and its use in the telephone interview
31. Reliability of the Barthel Index Outcome Measure selected for the NINDS t-PA Stroke Trial
32. Comparison of clinical and neuroradiological findings in first-ever stroke: A population-based study
33. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: A correlative PET-CT study with voxel-based data analysis
34. Mapping the ischaemic penumbra with PET: Implications for acute stroke treatment
35. Ischemic core and penumbra in human stroke
36. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra
37. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial